Your browser doesn't support javascript.
loading
Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs.
Knight, Lauren L; Wagner, Katherine; Leyva, Yuridia; Bruce, Veronica R; White, Kirsten A M; Talamantes, Yvonne S; Price, Brittany; Page, Kimberly; Carvour, Martha L.
Afiliação
  • Knight LL; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Wagner K; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Leyva Y; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Bruce VR; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • White KAM; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Talamantes YS; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Price B; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Page K; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • Carvour ML; 1 University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Health Promot Pract ; 19(6): 815-822, 2018 11.
Article em En | MEDLINE | ID: mdl-30227752
ABSTRACT

INTRODUCTION:

Young adults who inject drugs and live in rural communities are at high risk for hepatitis C virus (HCV) infection. Recent changes in HCV treatment must be communicated within these communities to improve access to care and reduce HCV transmission.

METHODS:

Field workers in the ¡VÁLE! Hepatitis Treatment and Integrated Prevention Services study identified frequently asked questions (FAQs) posed by young-adult participants at high risk for HCV during screening and educational sessions. From 2016 to 2018, 183 young adults (44.3% women; 85.8% Latino/a) younger than 30 years who inject drugs and reside in Rio Arriba or Doña Ana counties in New Mexico were enrolled. The research team compiled deidentified questions during field enrollments.

RESULTS:

FAQs were reviewed and categorized into four major domains, including risk/prevention, screening, treatment, and reinfection. FAQs were addressed by a team of medical and public health professionals, using the most current research and recommendations.

CONCLUSIONS:

These FAQs address important gaps in HCV knowledge among young adults who are at high risk for infection. The FAQs also highlight the importance of risk reduction counseling provided by frontline public health providers as well as access to safe and effective HCV treatments for young adults who inject drugs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hispânico ou Latino / Abuso de Substâncias por Via Intravenosa / Hepatite C / Promoção da Saúde Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hispânico ou Latino / Abuso de Substâncias por Via Intravenosa / Hepatite C / Promoção da Saúde Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article